Shardul Amarchand Mangaldas & Co. (SAM) advised Main Capital Partners and its portfolio company, BizzDesign, on Indian law aspects for the aacquisition of business assets relating to the Alfabet Business in India from subsidiaries of Software GmbH (formerly Software AG) (“SAG”), as part of the global acquisition of the software business Alfabet (market leader in… Read More +

Shardul Amarchand Mangaldas & Co. (SAM) advised Attentive.ai group on their Series B fundraising round totaling approximately USD 30.5 million, led by Insight Partners, with participation from InfoEdge, Vertex and Tenacity Ventures.   The investment supports Attentive.ai group’s expansion as an AI-based SaaS platform offering cloud-based software for landscape and construction management.   The SAM… Read More +

Shardul Amarchand Mangaldas & Co. (SAM) advised Medi Assist Healthcare Services Limited (“Medi Assist”) on its ~INR 198 crores fundraise through preferential issue of equity shares to Massachusetts Institute of Technology (MIT) and 238 Plan Associates LLC (collectively, the “Investors”). The transaction involved the issuance and allotment of fully paid-up equity shares of Medi Assist… Read More +

Shardul Amarchand Mangaldas & Co. (SAM) advised Nephrocare Health Services Limited (“Nephroplus”) on its initial public offering aggregating to approximately US$ 95.99 million (₹ 8,710.48 million), comprising a fresh issue of ₹ 3,534.05 million and an offer for sale of ₹ 5,176.43 million.   SAM acted as legal counsel to Nephroplus on Indian law aspects of the transaction,… Read More +

Shardul Amarchand Mangaldas & Co. (“SAM”) acted as Indian legal counsel to the 18-banks syndicate on the initial public offering of ICICI Prudential Asset Management Company Limited (“ICICI Prudential AMC”), comprising an offer for sale of equity shares aggregating to ₹ 10, 602 crore (approx. USD 1.20 billion) by Prudential Corporation Holdings Limited, the promoter… Read More +